Akebia Therapeutics, Inc. (AKBA)

Trade AKBA now with
12/13/2018 7:07:36 AM Akebia Therapeutics And Keryx Biopharmaceuticals Complete Merger
12/11/2018 12:07:54 PM Akebia Therapeutics Shareholders Approve Merger With Keryx
11/30/2018 8:56:04 AM Glass Lewis Joins ISS In Recommending Akebia Shareholders Vote For” Proposed Merger With Keryx
11/29/2018 7:04:57 AM ISS Recommends Akebia Shareholders Vote For Proposed Merger With Keryx
11/29/2018 7:03:34 AM ISS Recommends That Keryx Biopharmaceuticals Stockholders Vote “FOR” The Proposed Merger With Akebia Therapeutics
8/28/2018 4:13:32 PM Akebia Therapeutics Appoints Cynthia Smith To Its Board Of Directors
6/28/2018 7:09:39 AM Akebia Therapeutics, Trading Expected To Resume At 7:30 AM ET
6/28/2018 7:07:24 AM Akebia Therapeutics, Keryx Biopharmaceuticals To Combine In An All-stock Merger
6/28/2018 7:01:16 AM Akebia Therapeutics, Trading Halted Pending News
3/23/2018 8:02:12 AM Akebia Therapeutics Announces Pricing Of Public Offering Of 8.5 Mln Shares At $10.50/Shr
3/22/2018 4:27:49 PM Akebia Therapeutics Announces Proposed Public Offering Of Common Stock
1/4/2018 7:05:11 AM Akebia Therapeutics Announces Positive Top-Line Results From Phase 2 Study Of Vadadustat
11/7/2014 9:36:09 AM Nomura Reiterates Akebia Therapeutics, Inc. (AKBA) At Buy With $39 Price Target
4/14/2014 10:51:24 AM Nomura Initiates Akebia Therapeutics, Inc. (AKBA) At Buy With $39 Price Target